Evidence map›Paper›PMID 41583498›Full record

ArticleFrontiers in immunology2025

Large-scale screening of HBV epitopes restricted by multiple prevalent HLA-B/C allotypes and routine detection of HBV-specific T cells in CHB patients.

Yandan Wu, Yu Zhao, Ruixue Ji, Pinqing Li, Huijuan Chen, Fangping Yue, Yi Wu, Jie Qiu, Chuanlai Shen

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yandan WuDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.
Yu ZhaoDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.
Ruixue JiDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.
Pinqing LiDepartment of Hepatitis, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Huijuan ChenDepartment of Infectious Diseases, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Fangping YueDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.
Yi WuDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.
Jie QiuDepartment of Hepatitis, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Chuanlai ShenDepartment of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: In our previous work, a total of 103 CD8 Methods: CD8 Results: A total of 89 novel CD8 Conclusions: The proposed method holds great potential for facilitating routine evaluation of HBV-specific CD8

Indexed as

CD8-Positive T-LymphocytesEpitopes, T-LymphocyteHepatitis B, ChronicHepatitis B virusHLA-B AntigensAdultEnzyme-Linked Immunospot AssayFemaleHumansMaleMiddle AgedEpitopes, T-LymphocyteHLA-B AntigensELISpot assayhepatitis B virusHLA-AHLA-BHLA-CT-cell epitope

Identifiers

PMID41583498
PMCPMC12827522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.